TABLE D-1 Critical Studies and Uncertainty Factors Used in Developing AEGLs for GB

Critical Study

 

Uncertainty Factors (UFs)

Standard and Study

End Point

Severity

Species

Gender

Test Duration

Temporal Extrapolation

Intraspecies

Interspecies

MF

Total UF

AEGL-1 Mioduszewski et al. 2000

EC50 for miosis

Nondisabling (miosis is the first measurable change in the continuum of response to anticholinesterase response)

Adult rat

Female

10, 60, and 240 min

Cn × t =k; n = 2; from 10 to 30 min and from 4 to 8 hours

10

1

1

10

AEGL-2 Baker and Sedgwick 1996

LOAEL for miosis, dyspnea, RBC-ChE inhibition, single fiber electromyography changes

Disabling (single fiber electromyography changes as early indicator of exposures that could result in more significant effects)

Human

NR

10-30 min

Cn × t =k; n = 2; from 30 min to all durations

10

1

1

10

AEGL-3 Mioduszewski et al. 2000, 2001, 2002

LC01 and LC50

Lethal

Rat

Female

10, 30, 60, 90, 240, and 360 min

Cn × t =k; n = 2; from 6 to 8 hours

10

3

1

30

Abbreviations: EC50, effective concentration for a 50% response; LC01, lethal concentration to 1% of exposed subjects; LC50, lethal concentration to 50% of exposed subjects; MF, modifying factor; NR, not reported; RBC-ChE, red blood celll cholinesterase.

Source: Data obtained from NRC 2003.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement